featured
Addition of Bevacizumab to Erlotinib as First-Line Treatment for EGFR-Mutated Advanced Nonsquamous NSCLC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
- Impact of Smoking Status on the Efficacy of EGFR-TKI Plus Angiogenesis Inhibitor Combination Therapy in Advanced NSCLC
- Effect of Smoking Habits on the Efficacy of EGFR TKI Plus Anti-Angiogenic Agent in Advanced EGFR-Mutant NSCLC
- Smoking History and Overall Survival in Patients Receiving First-Line Pembrolizumab for Advanced NSCLC
Disclosure statements are available on the authors' profiles:
Journal of Thoracic Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Addition of bevacizumab to erlotinib as first-line treatment of patients with EGFR-mutated advanced nonsquamous non-small cell lung cancer. The BEVERLY multicenter randomized phase III trial
J Thorac Oncol 2022 Jun 01;[EPub Ahead of Print], MC Piccirillo, L Bonanno, MC Garassino, G Esposito, C Dazzi, L Cavanna, MA Burgio, F Rosetti, S Rizzato, F Morgillo, S Cinieri, A Veccia, M Papi, G Tonini, V Gebbia, S Ricciardi, D Pozzessere, A Ferro, C Proto, R Costanzo, M D'Arcangelo, M Proietto, P Gargiulo, R Di Liello, L Arenare, F De Marinis, L Crinò, F Ciardiello, N Normanno, C Gallo, F Perrone, C Gridelli, A MorabitoFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.